Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
VanEck Oil Services ETF
OIH
5
ProShares Ultra Energy
DIG
US Stock MarketDetailed Quotes
Nkarta (NKTX)
- 2.860
- +0.100+3.62%
Close Jun 12 15:59 ET
- 2.860
- 0.0000.00%
Post 16:10 ET
204.62MMarket Cap-2.12P/E (TTM)
2.950High2.710Low677.58KVolume2.760Open2.760Prev Close1.94MTurnover1.12%Turnover RatioLossP/E (Static)71.55MShares3.65052wk High0.72P/B172.88MFloat Cap1.63052wk Low--Dividend TTM60.45MShs Float79.160Historical High--Div Yield TTM8.70%Range %1.280Historical Low2.857Avg Price1Lot Size
About Nkarta Company
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
Company Profile
SymbolNKTX
Company NameNkarta
Listing DateJul 10, 2020
Issue Price18.00
ISINUS65487U1088
Founded2005
CEOMr. Paul J. Hastings
MarketNASDAQ
Employees108
Fiscal Year Ends12-31
Address1150 Veterans Boulevard
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080
Phone1-925-407-1049
Websitehttp://www.nkartatx.com
Company Executives
- Name
- Position
- Salary
- Paul J. Hastings
- Chief Executive Officer and Director
- 2.98M
- Dr. Shawn Rose, M.D.,PhD
- Chief Medical Officer and Head, Research and Development
- 1.22M
- Dr. Nadir Mahmood, PhD
- President, Chief Financial Officer and Principal Accounting Officer
- 1.40M
- Dr. Ali Behbahani, M.B.A.,M.D.
- Chairman of the Board
- 154.79K
- Leone D Patterson, M.B.A.
- Independent Director
- 122.29K
- Angela Thedinga, M.B.A.,M.P.A.
- Independent Director
- 132.79K
- Dr. Zachary Scheiner, PhD
- Independent Director
- 118.29K
- Dr. Simeon J. George, M.B.A.,M.D.
- Independent Director
- 113.29K
- Dr. Michael Dybbs, PhD
- Independent Director
- 130.29K
- Dr. George Vratsanos, M.D.
- Independent Director
- 119.29K
Market Insights
China Concept Stocks China Concept Stocks
Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation. Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation.
View More
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
The U.S.-Iran negotiations have entered a critical window! According to Bloomberg, both sides are close to signing a memorandum of understan
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm